From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Molar mass404.5 g/mol g·mol−1
3D model (JSmol)

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3]

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[4][5]


Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[6]

See also[edit]


  1. ^ "APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.
  2. ^ "Patent WO/2009/106980 - Indazole derivatives".
  3. ^ "EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert". Retrieved 24 June 2015.
  4. ^ "EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert". Retrieved 24 June 2015.
  5. ^ "EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert". Retrieved 24 June 2015.
  6. ^ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015.